Yasushi Furukawa
Wakayama Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yasushi Furukawa.
FEBS Letters | 2010
Ying Wang; Masahiro Nishi; Asako Doi; Takeshi Shono; Yasushi Furukawa; Takeshi Shimada; Hiroto Furuta; Hideyuki Sasaki; Kishio Nanjo
Ghrelin inhibits insulin secretion partly via induction of IA‐2β. However, the orexigenic effect of ghrelin is mediated by the AMP‐activated protein kinase (AMPK)–uncoupling protein 2 (UCP2) pathway. Here, we demonstrate that ghrelins inhibitory effect on insulin secretion also occurs through the AMPK‐UCP2 pathway. Ghrelin increased AMPK phosphorylation and UCP2 mRNA expression in MIN6 insulinoma cells. Overexpression or downregulation of UCP2 attenuated or enhanced insulin secretion, respectively. Furthermore, AMPK activator had a similar effect to ghrelin on UCP2 and insulin secretion in MIN6 cells. In conclusion, ghrelins inhibitory effect on insulin secretion is partly mediated by the AMPK‐UCP2 pathway, which is independent of the IA‐2β pathway.
Endocrine Journal | 2016
Tetsurou Satoh; Osamu Isozaki; Atsushi Suzuki; Shu Wakino; Tadao Iburi; Kumiko Tsuboi; Naotetsu Kanamoto; Hajime Otani; Yasushi Furukawa; Satoshi Teramukai; Takashi Akamizu
Thyroid storm is an endocrine emergency which is characterized by multiple organ failure due to severe thyrotoxicosis, often associated with triggering illnesses. Early suspicion, prompt diagnosis and intensive treatment will improve survival in thyroid storm patients. Because of its rarity and high mortality, prospective intervention studies for the treatment of thyroid storm are difficult to carry out. We, the Japan Thyroid Association and Japan Endocrine Society taskforce committee, previously developed new diagnostic criteria and conducted nationwide surveys for thyroid storm in Japan. Detailed analyses of clinical data from 356 patients revealed that the mortality in Japan was still high (∼11%) and that multiple organ failure and acute heart failure were common causes of death. In addition, multimodal treatment with antithyroid drugs, inorganic iodide, corticosteroids and beta-adrenergic antagonists has been suggested to improve mortality of these patients. Based on the evidence obtained by nationwide surveys and additional literature searches, we herein established clinical guidelines for the management of thyroid storm. The present guideline includes 15 recommendations for the treatment of thyrotoxicosis and organ failure in the central nervous system, cardiovascular system, and hepato-gastrointestinal tract, admission criteria for the intensive care unit, and prognostic evaluation. We also proposed preventive approaches to thyroid storm, roles of definitive therapy, and future prospective trial plans for the treatment of thyroid storm. We hope that this guideline will be useful for many physicians all over the world as well as in Japan in the management of thyroid storm and the improvement of its outcome.
Clinical Endocrinology | 2016
Osamu Isozaki; Tetsurou Satoh; Shu Wakino; Atsushi Suzuki; Tadao Iburi; Kumiko Tsuboi; Naotetsu Kanamoto; Hajime Otani; Yasushi Furukawa; Satoshi Teramukai; Takashi Akamizu
Thyroid storm (TS) is a life‐threatening endocrine emergency. This study aimed to achieve a better understanding of the management of TS by analyzing therapeutic modalities and prognoses reported by nationwide surveys performed in Japan.
Diabetes Research and Clinical Practice | 2009
Takeshi Shimada; Yasushi Furukawa; Hiroto Furuta; Kazuki Yasuda; Shohei Matsuno; Akiko Kusuyama; Asako Doi; Masahiro Nishi; Hideyuki Sasaki; Tokio Sanke; Kishio Nanjo
The Met55Val polymorphism in the small ubiquitin-like modifier 4 (SUMO4) gene has been associated with susceptibility not only to type 1 diabetes, but also to type 2 diabetes and diabetic nephropathy. We tried to confirm the association with susceptibility to type 2 diabetes and to investigate its role in diabetic vascular complications. The polymorphism was genotyped in two independent Japanese samples (Wakayama and Tokyo) by the TaqMan method. Susceptibility to type 2 diabetes and prevalence of diabetic vascular complications (coronary heart disease, cerebral infarction, retinopathy, and nephropathy) were evaluated by case-control study and multivariate logistic regression analysis, respectively. There were no significant differences in the frequency of alleles or genotypes between patients and controls. The Val allele, however, was associated with higher prevalence of coronary heart disease in patients in both groups (Wakayama, n=423, odds ratio, 1.64; 95% confidence interval, 1.02-2.64; P=0.041; Tokyo, n=451, odds ratio, 1.58; 95% CI, 1.07-2.34; P=0.021, in an additive model, respectively). No significant associations were observed with other diabetic vascular complications. Although association of the polymorphism with susceptibility to type 2 diabetes or nephropathy was not replicated, an association of the polymorphism with risk of coronary heart disease in type 2 diabetes is suggested.
Endocrine Journal | 2015
Ken Takeshima; Hiroyuki Ariyasu; Hidefumi Inaba; Yuko Inagaki; Hiroyuki Yamaoka; Yasushi Furukawa; Asako Doi; Hiroto Furuta; Masahiro Nishi; Takashi Akamizu
Immunoglobulin G4-related disease (IgG4-RD) is characterized by elevated serum IgG4 levels, IgG4-positive plasmacytes, and lymphocyte infiltration into multiple organs. IgG4 thyroiditis is a subset of patients with Hashimotos thyroiditis (HT) who exhibited histopathological features of IgG4-RD; its source of serum IgG4 is suggested to be the thyroid gland. Although a relationship between IgG4-RD and IgG4 thyroiditis has been reported, the meaning of serum IgG4 in HT is uncertain. In this report, we prospectively evaluated serum IgG4 levels and clinical features of patients with HT. A total of 149 patients with HT were prospectively recruited into this study. According to the comprehensive diagnostic criteria of IgG4-RD, patients were divided into two groups: elevated IgG4 (>135 mg/dL) and non-elevated IgG4 (≤135 mg/dL). Median serum IgG4 levels of HT patients were 32.0 mg/dL (interquartile range, 20.0-65.0), with a unimodal non-normal distribution. Six patients (4.0%) had elevated serum IgG4 levels above 135 mg/dL. The elevated IgG4 group was older and exhibited enlarged hypoechoic areas in the thyroid gland, as revealed by ultrasonography, relative to the non-elevated IgG4 group. Levothyroxine (L-T4) replacement doses and titers of anti-thyroid antibodies did not differ significantly between the two groups. Two out of six HT patients with elevated serum IgG4 levels had extra-thyroid organ involvement as seen in IgG4-RD. In conclusion, HT patients with elevated serum IgG4 levels shared clinical features with both IgG4-RD and IgG4 thyroiditis. Longer follow-up periods and histopathological assessments are needed to further understand the meaning of elevated serum IgG4 levels in HT.
Endocrinology, Diabetes & Metabolism Case Reports | 2017
Shintaro Kawai; Hiroyuki Ariyasu; Yasushi Furukawa; Reika Yamamoto; Shinsuke Uraki; Ken Takeshima; Kenji Warigaya; Yuji Nakamoto; Takashi Akamizu
Summary Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by renal phosphate wasting leading to hypophosphatemia due to excessive actions of fibroblast growth factor 23 (FGF23) produced by the tumors. Although the best way of curing TIO is complete resection, it is usually difficult to detect the culprit tumors by general radiological modalities owing to the size and location of the tumors. We report a case of TIO in which the identification of the tumor by conventional imaging studies was difficult. Nonetheless, a diagnosis was made possible by effective use of multiple modalities. We initially suspected that the tumor existed in the right dorsal aspect of the scapula by 68Ga-DOTATOC positron emission tomography/computed tomography (68Ga-DOTATOC-PET/CT) and supported the result by systemic venous sampling (SVS). The tumor could also be visualized by 3T-magnetic resonance imaging (MRI), although it was not detected by 1.5T-MRI, and eventually be resected completely. In cases of TIO, a stepwise approach of 68Ga-DOTATOC-PET/CT, SVS and 3T-MRI can be effective for confirmation of diagnosis. Learning points: TIO shows impaired bone metabolism due to excessive actions of FGF23 produced by the tumor. The causative tumors are seldom detected by physical examinations and conventional radiological modalities. In TIO cases, in which the localization of the culprit tumors is difficult, 68Ga-DOTATOC-PET/CT should be performed as a screening of localization and thereafter SVS should be conducted to support the result of the somatostatin receptor (SSTR) imaging leading to increased diagnosability. When the culprit tumors cannot be visualized by conventional imaging studies, using high-field MRI at 3T and comparing it to the opposite side are useful after the tumor site was determined.
Molecular and Cellular Endocrinology | 2017
Mika Bando; Hiroshi Iwakura; Yoko Ueda; Hiroyuki Ariyasu; Hidefumi Inaba; Yasushi Furukawa; Hiroto Furuta; Masahiro Nishi; Takashi Akamizu
In animal models, ghrelin production is suppressed by LPS administration. To elucidate the detailed molecular mechanisms involved in the phenomenon, we investigated the effects of LPS and LPS-inducible cytokines, including TNF-α, IL-1β, and IL-6, on the expression of ghrelin in the ghrelin-producing cell line MGN3-1. These cells expressed IL-1R, and IL-1β significantly suppressed ghrelin mRNA levels. The suppressive effects of IL-1β were attenuated by knockdown of IKKβ, suggesting the involvement of the NF-κB pathway. These results suggested that IL-1β is a major regulator of ghrelin expression during inflammatory processes.
The Journal of Clinical Endocrinology and Metabolism | 2008
Yasushi Furukawa; Takeshi Shimada; Hiroto Furuta; Shohei Matsuno; Akiko Kusuyama; Asako Doi; Masahiro Nishi; Hideyuki Sasaki; Tokio Sanke; Kishio Nanjo
Thyroid | 2014
Ken Takeshima; Hidefumi Inaba; Yasushi Furukawa; Masahiro Nishi; Hiroyuki Yamaoka; Waka Miyamoto; Takayuki Ota; Asako Doi; Hiromichi Kawashima; Hiroyuki Ariyasu; Hisao Wakasaki; Hiroto Furuta; Taisei Nakao; Hideyuki Sasaki; Takashi Akamizu
Internal Medicine | 2013
Hidefumi Inaba; Takahiro Hayakawa; Waka Miyamoto; Ken Takeshima; Hiroyuki Yamaoka; Yasushi Furukawa; Hiromichi Kawashima; Hiroyuki Ariyasu; Hisao Wakasaki; Hiroto Furuta; Masahiro Nishi; Taisei Nakao; Hideyuki Sasaki; Yuka Okada; Kazuto Matsunaga; Yasushi Nakamura; Takashi Akamizu